Literature DB >> 24417965

Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis.

Shahriar Absar1, Young M Kwon2, Fakhrul Ahsan3.   

Abstract

In this study, we have developed an albumin-camouflaged/thrombin-triggered delivery system for site-specific delivery of tissue plasminogen activator (tPA). The camouflaged construct is expected to suppress tPA's enzymatic activity in the systemic circulation but regenerate its thrombolytic action upon contact with thrombin present on the thrombus. tPA was camouflaged with human serum albumin (HSA) via a thrombin-cleavable peptide (GFPRGFPAGGCtPA). The surface of the albumin molecule was decorated with a homing peptide (CQQHHLGGAKQAGDV) that binds with GPIIb/IIIa expressed on activated platelets. To avoid non-specific interactions, the unpaired cysteine-34 of HSA was permanently blocked by iodoacetamide and the primary amines were temporarily masked with citraconic anhydride. Shielding with HSA suppressed 75% of tPA's activity which, upon contact with 25 nM thrombin, was regenerated to ~90% of that of native tPA. The fibrin agar plate assay further confirmed the thrombin-mediated release of tPA from the camouflaged construct. The integrity of camouflaged construct was maintained in human plasma or blood. The fluorescence microscopic studies confirmed the binding affinity of camouflaged tPA with the activated platelets. Furthermore, when evaluated in a rat thrombosis model, the thrombolytic activity of camouflaged tPA was similar to that of native tPA. However, the degradation of circulating fibrinogen was reduced by 2-fold with HSA-decorated tPA compared with that of native tPA, which is an indication of reduced risk of hemorrhagic incidence. This proof-of-principle study suggests that the activity of tPA can be suppressed by HSA and regenerated by thrombin present at the thrombus.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Albumin-based delivery; Protein delivery; Responsive delivery system; Targeted thrombolysis; Tissue plasminogen activator; Triggered release

Mesh:

Substances:

Year:  2014        PMID: 24417965     DOI: 10.1016/j.jconrel.2013.12.036

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  15 in total

Review 1.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

2.  Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.

Authors:  Shan Liu; Xiaozhou Feng; Rong Jin; Guohong Li
Journal:  Expert Opin Drug Deliv       Date:  2017-09-28       Impact factor: 6.648

Review 3.  Engineered microparticles and nanoparticles for fibrinolysis.

Authors:  Dante Disharoon; David W M Marr; Keith B Neeves
Journal:  J Thromb Haemost       Date:  2019-10-07       Impact factor: 5.824

Review 4.  Thrombolytic Agents: Nanocarriers in Controlled Release.

Authors:  Soodabeh Hassanpour; Han-Jun Kim; Arezoo Saadati; Peyton Tebon; Chengbin Xue; Floor W van den Dolder; Jai Thakor; Behzad Baradaran; Jafar Mosafer; Amir Baghbanzadeh; Natan Roberto de Barros; Mahmoud Hashemzaei; Kang Ju Lee; Junmin Lee; Shiming Zhang; Wujin Sun; Hyun-Jong Cho; Samad Ahadian; Nureddin Ashammakhi; Mehmet R Dokmeci; Ahad Mokhtarzadeh; Ali Khademhosseini
Journal:  Small       Date:  2020-08-12       Impact factor: 13.281

Review 5.  Tissue plasminogen activator-based clot busting: Controlled delivery approaches.

Authors:  Ibrahim M El-Sherbiny; Islam E Elkholi; Magdi H Yacoub
Journal:  Glob Cardiol Sci Pract       Date:  2014-10-16

6.  Thrombus Degradation by Fibrinolytic Enzyme of Stenotrophomonas sp. Originated from Indonesian Soybean-Based Fermented Food on Wistar Rats.

Authors:  Florensia Nailufar; Raymond R Tjandrawinata; Maggy T Suhartono
Journal:  Adv Pharmacol Sci       Date:  2016-08-21

7.  Novel Thrombolytic Drug Based on Thrombin Cleavable Microplasminogen Coupled to a Single-Chain Antibody Specific for Activated GPIIb/IIIa.

Authors:  Thomas Bonnard; Zachary Tennant; Be'Eri Niego; Ruchi Kanojia; Karen Alt; Shweta Jagdale; Lok Soon Law; Sheena Rigby; Robert Lindsay Medcalf; Karlheinz Peter; Christoph Eugen Hagemeyer
Journal:  J Am Heart Assoc       Date:  2017-02-03       Impact factor: 5.501

8.  Synthesis and evaluation of cationic polymeric micelles as carriers of lumbrokinase for targeted thrombolysis.

Authors:  Yang Pan; Xiahui Wang; Zongning Yin
Journal:  Asian J Pharm Sci       Date:  2018-05-16       Impact factor: 6.598

9.  Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy.

Authors:  Yu Huang; Boram Gu; Isabelle I Salles-Crawley; Kirk A Taylor; Li Yu; Jie Ren; Xuhan Liu; Michael Emerson; Colin Longstaff; Alun D Hughes; Simon A Thom; Xiao Yun Xu; Rongjun Chen
Journal:  Sci Adv       Date:  2021-06-02       Impact factor: 14.136

10.  Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.

Authors:  Huai-An Chen; Yunn-Hwa Ma; Tzu-Yuan Hsu; Jyh-Ping Chen
Journal:  Int J Mol Sci       Date:  2020-04-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.